arrow
B

Babar Bashir

thomas jefferson university
H指数:19
被引数:3,231

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12Cemutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101

Sotorasib (soto)、panitumumab (pani) 和 FOLFIRI 在一线(1L)KRAS G12C突变转移性结直肠癌(mCRC)中的安全性与有效性:CodeBreaK 101的区域性分析

2024-12-010
PRE
Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors

接受自行车毒素偶联物(BTCs)BT8009或BT5528单药治疗的晚期实体瘤患者中出现的周围神经病变(PN)。

2024-09-011
PRE
EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study

EphA2靶向环形分子毒素偶联物(BTC)BT5528在晚期实体瘤患者(pts)中的I/II期研究

2024-09-010
PRE
Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective

乳腺癌放射性皮炎干预措施的改良德尔菲共识:加拿大专家视角

2024-09-010
PRE
Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study

Sotorasib(soto)、panitumumab(pani)和FOLFIRI在KRAS G12C突变型转移性结直肠癌(mCRC)的一线(1L)治疗中的安全性及疗效分析:来自Ib期CodeBreaK 101研究的数据

2024-09-011
PRE
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis
2024-07-011
OAAI
Trial in progress: First-in-human phase I dose-escalation study of a novel Bicycle toxin conjugate (BT5528) targeting EphA2 in patients with advanced solid tumors
2023-12-010
PRE
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

乳腺癌和新型冠状病毒肺炎患者的临床特征,种族不平等和结局: 新型冠状病毒肺炎和癌症联盟 (CCC19) 队列研究

2023-10-172
OA